123 related articles for article (PubMed ID: 9454657)
41. Tumor markers CA 125 and CA 19-9 in cord blood and during infancy: developmental changes and use in pediatric germ cell tumors.
Lahdenne P; Pitkänen S; Rajantie J; Kuusela P; Siimes MA; Lanning M; Heikinheimo M
Pediatr Res; 1995 Nov; 38(5):797-801. PubMed ID: 8552451
[TBL] [Abstract][Full Text] [Related]
42. [The plasma levels and diagnostic utility of stem cell factor and macrophage--colony stimulating factor in endometrial cancer patients].
Lawicki S; Bedkowska E; Gacuta-Szumarska E; Czygier M; Szmitkowski M
Przegl Lek; 2007; 64(12):987-90. PubMed ID: 18595499
[TBL] [Abstract][Full Text] [Related]
43. Tumor marker levels in post-chemotherapy cystic masses: clinical implications for patients with germ cell tumors.
Beck SD; Patel MI; Sheinfeld J
J Urol; 2004 Jan; 171(1):168-71. PubMed ID: 14665869
[TBL] [Abstract][Full Text] [Related]
44. Comprehensive staging allows for excellent outcome in patients with localized malignant germ cell tumor of the ovary.
Palenzuela G; Martin E; Meunier A; Beuzeboc P; Laurence V; Orbach D; Frappaz D
Ann Surg; 2008 Nov; 248(5):836-41. PubMed ID: 18948812
[TBL] [Abstract][Full Text] [Related]
45. Preoperative serum thrombopoietin levels are higher in patients with ovarian cancer than with benign cysts.
Tsukishiro S; Suzumori N; Nishikawa H; Arakawa A; Suzumori K
Eur J Obstet Gynecol Reprod Biol; 2008 Sep; 140(1):67-70. PubMed ID: 16359773
[TBL] [Abstract][Full Text] [Related]
46. Circulating calprotectin in ovarian carcinomas and borderline tumors of the ovary.
Ødegaard E; Davidson B; Elgaaen BV; Fagerhol MK; Engh V; Onsrud M; Staff AC
Am J Obstet Gynecol; 2008 Apr; 198(4):418.e1-7. PubMed ID: 18241816
[TBL] [Abstract][Full Text] [Related]
47. [Within-day and day-to-day variations of serum M-CSF levels in healthy volunteers].
Aihara T; Misago M; Hanamura T; Kikuchi M; Toshimitsu H; Ootani H; Chiba S; Eto S
Rinsho Byori; 1993 Mar; 41(3):268-72. PubMed ID: 8345656
[TBL] [Abstract][Full Text] [Related]
48. [Ovarian tumors in children].
Fabbro MA; Costa L; Spata E; Cimaglia ML; Donadio P
Pediatr Med Chir; 1996; 18(2):151-4. PubMed ID: 8767576
[TBL] [Abstract][Full Text] [Related]
49. [Serum ribonuclease in patients with malignant tumor of the ovary].
Liu SS; Cai GR
Zhonghua Fu Chan Ke Za Zhi; 1991 Jan; 26(1):17-20, 61. PubMed ID: 2004569
[TBL] [Abstract][Full Text] [Related]
50. Mixed germ cell malignancy of the ovary concurrent with pregnancy.
Horbelt D; Delmore J; Meisel R; Cho S; Roberts D; Logan D
Obstet Gynecol; 1994 Oct; 84(4 Pt 2):662-4. PubMed ID: 9205440
[TBL] [Abstract][Full Text] [Related]
51. Hematopoietic cytokines as tumor markers in gynecological malignancies: a multivariate analysis with ROC curve in endometrial cancer patients.
Lawicki S; Będkowska GE; Gacuta-Szumarska E; Szmitkowski M
Growth Factors; 2012 Feb; 30(1):29-36. PubMed ID: 22010785
[TBL] [Abstract][Full Text] [Related]
52. Macrophage colony-stimulating factor as a tumor marker for squamous cell carcinoma of the head and neck.
Kuropkat C; Dünne AA; Plehn S; Ossendorf M; Herz U; Renz H; Werner JA
Tumour Biol; 2003; 24(5):236-40. PubMed ID: 15001836
[TBL] [Abstract][Full Text] [Related]
53. Serum sICAM-1 (soluble intercellular adhesion molecule-1) and M-CSF (macrophage colony-stimulating growth factor) throughout monitoring of 34 non-serous ovarian cancers.
Callet N; Delaunay J; Pichon MF
Eur J Gynaecol Oncol; 2000; 21(2):135-40. PubMed ID: 10843471
[TBL] [Abstract][Full Text] [Related]
54. Seven tumor markers in benign and malignant germ cell tumors of the ovary.
Kawai M; Kano T; Kikkawa F; Morikawa Y; Oguchi H; Nakashima N; Ishizuka T; Kuzuya K; Ohta M; Arii Y
Gynecol Oncol; 1992 Jun; 45(3):248-53. PubMed ID: 1319383
[TBL] [Abstract][Full Text] [Related]
55. Malignant germ cell tumors of the ovary: Hacettepe hospital experience.
Ayhan A; Tuncer ZS; Yanik F; Bükülmez O; Yanik A; Küçükali T
Acta Obstet Gynecol Scand; 1995 May; 74(5):384-90. PubMed ID: 7778434
[TBL] [Abstract][Full Text] [Related]
56. OVX1, macrophage-colony stimulating factor, and CA-125-II as tumor markers for epithelial ovarian carcinoma: a critical appraisal.
van Haaften-Day C; Shen Y; Xu F; Yu Y; Berchuck A; Havrilesky LJ; de Bruijn HW; van der Zee AG; Bast RC; Hacker NF
Cancer; 2001 Dec; 92(11):2837-44. PubMed ID: 11753957
[TBL] [Abstract][Full Text] [Related]
57. [A research on serum, urine and tumor tissue hyaluronate assays for detecting malignant ovarian tumors].
He W; Chang J; Zhang J
Zhonghua Fu Chan Ke Za Zhi; 1995 Mar; 30(3):161-3. PubMed ID: 7796650
[TBL] [Abstract][Full Text] [Related]
58. Elevation of multiple serum markers in patients with stage I ovarian cancer.
Woolas RP; Xu FJ; Jacobs IJ; Yu YH; Daly L; Berchuck A; Soper JT; Clarke-Pearson DL; Oram DH; Bast RC
J Natl Cancer Inst; 1993 Nov; 85(21):1748-51. PubMed ID: 8411259
[TBL] [Abstract][Full Text] [Related]
59. Comparative evaluation of plasma levels and diagnostic values of macrophage-colony stimulating factor in patients with breast cancer and benign tumors.
Ławicki S; Czygier M; Bedkowska E; Wojtukiewicz M; Szmitkowski M
Pol Arch Med Wewn; 2008 Sep; 118(9):464-9. PubMed ID: 18846980
[TBL] [Abstract][Full Text] [Related]
60. Macrophage colony-stimulating factor as a marker of ovarian carcinoma.
Ookura N; Nishimura H; Kiyozuka Y; Komai K; Ushijima K; Sugiyama T; Nishida T; Yakushiji M
Oncol Rep; 1997; 4(5):967-71. PubMed ID: 21590177
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
